Deregulation of the cell cycle machinery, which has been linked to dysregulation of cyclin-
dependent kinases (CDKs), is a defining characteristic of cancer, eventually promoting …

Chemotherapy-induced damage of hematopoietic stem and progenitor cells (HPSCs) often
results in myelosuppression that adversely affects patient health and quality of life. Currently …

Purpose In a phase II trial in patients with metastatic triple-negative breast cancer (mTNBC;
NCT02978716), administering trilaciclib prior to gemcitabine plus carboplatin (GCb) …

Chemotherapy‐induced myelosuppression is an acute, dose‐limiting toxicity of
chemotherapy regimens used in the treatment of extensive‐stage small cell lung cancer (ES …

Lung cancer is the leading cause of cancer-related deaths worldwide, and∼ 85% of lung
cancers are classified as nonsmall cell lung cancer (NSCLC). These malignancies can …

This study aimed to analyze potential ethnic disparities in the dose–exposure–response
relationships of trilaciclib, a first-in-class intravenous cyclin-dependent kinase 4/6 inhibitor …

Aims Trilaciclib is a first‐in‐class, intravenous cyclin‐dependent kinase 4/6 inhibitor that
provides multilineage protection from chemotherapy‐induced myelosuppression. This …

Abstract Background and Objective Trilaciclib is a cyclin-dependent kinase 4/6 inhibitor
indicated to decrease the incidence of chemotherapy-induced myelosuppression in patients …

Overview Oral cyclin-dependent kinase (CDK) 4/6 inhibitors are routinely used to treat
metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative …

Myelopreservation is always a good option when prescribing myelotoxic chemotherapy like
Topotecan. Bone marrow toxicity is one of the main hindrances in prescribing such …